Clinical use and toxicities of bortezomib in pediatric patients: a systematic review

Clinical use and toxicities of bortezomib in pediatric patients: a systematic review

BackgroundProteasome inhibitors (PIs) are FDA-approved to treat adult malignancies. The PI, Bortezomib (BTZ), has been used off-label in pediatric patients but its safety profile in these patients has yet to be systematically assessed. We sought to review the pediatric safety profile of BTZ based on...

Full description

Saved in:
Bibliographic Details
Main Authors: Zachary C. LeBlanc, Averill Clapp, Samantha Kaplan, Carrie J. Shawber, June K. Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Pharmacology
Subjects:
bortezomib
adverse events
pediatric safety
systematic review
proteasome inhibitors
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1661493/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items